Home » Topics » BioWorld Science

BioWorld Science
RSS

CTX-712: a novel promising CLK inhibitor for myeloid tumors

Dec. 31, 2019

BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder

Dec. 31, 2019

FDA approves OncoImmune's IND for anti-CTLA-4 antibody ONC-392

Dec. 31, 2019

Hookipa begins dosing in phase I/II trial of HB-201 for HPV16-positive cancers

Dec. 31, 2019

New phase Ib study evaluates mavorixafor with ibrutinib for Waldenstrom's macroglobulinemia

Dec. 31, 2019

Principia advances PRN-1008 for pemphigus with accelerated enrollment in phase III study

Dec. 31, 2019

Dybly describes new BRD4 inhibitors

Dec. 31, 2019

Qingdao Marine Biological Medicine Research presents EGF and FGF inhibitors

Dec. 31, 2019

BeiGene identifies new MAP4K1 inhibitors

Dec. 31, 2019

XW Laboratories discloses Exp1 receptor antagonists

Dec. 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...